-
Bristol-Myers Squibb Co. (BMS) of Princeton, NJ, recently showed through concept data that an attachment inhibitor BMS-488043 can have potent antiviral activity in HIV-1-infected patients.
-
While pharmaceutical companies and investigators work for a medication solution to the lipodystrophy and other metabolic disorders that plague some HIV patients, other research is looking into nonmedical solutions, such as vitamin use and exercise.
-
Recent research has shown that the microbicide field is alive with an array of prevention approaches to stopping HIV transmission during sexual intercourse. However, most researchers admit that while the pipeline of microbicide research is further along than the vaccine pipeline, it still could be five to 10 years before the ideal candidate is marketed.
-
Plan now to attend the HIV Prevention Leadership Summit, scheduled for June 16-19, 2004, at the Georgia World Congress Center in Atlanta.
-
Check the following web sites to get teen-friendly information to share with your adolescent patients.
-
Circle Aug. 12-15, 2004, on the calendar for the Minority Womens Health Summit sponsored by the Office of Public Health and Science, Office on Womens Health. The summit, Women of Color, Taking Action for a Healthier Life: Progress, Partnerships and Possibilities, will build upon the first national conference held in 1997.
-
Over the past decade, 18 states have obtained federal approval to extend eligibility for Medicaid-covered family planning services to individuals who would otherwise not be eligible. The first national evaluation of these efforts found that every one of the programs studied not only met the requirement that they not result in additional costs to the federal government, but actually saved money.
-
What is your approach when it comes to repeat doses of the levonorgestrel-only emergency contraceptive pill (ECP), Plan B (Womens Capital Corp., Washington, DC)? Comments on this question are offered by Contraceptive Technology Update Editorial Advisory Board members.
-
The Today contraceptive sponge awaits the results of a Food and Drug Administration (FDA) review to return to the shelves in the United States. After being approved by the FDA in 1983, the sponge achieved considerable popularity before production was discontinued in 1995. Since then, Allendale (NJ) Pharmaceuticals has purchased rights to the Today sponge and has been working to bring the product back to the United States.
-
